台湾生物技术公司GNTbm获得美国林业发展局批准,在第一阶段对抗淋巴瘤试验中测试新的口服癌症药物GNTbm-38。 A Taiwan biotech firm, GNTbm, gained U.S. FDA approval to test its new oral cancer drug, GNTbm-38, in Phase I trials for resistant lymphoma.

GNTbm是一家以台湾为基地的生物技术公司,已得到美国林业发展局的批准,同意开始第一阶段的临床试验,以试验其口服抗癌药物GNTbm-38,这是一种旨在增强免疫系统抗癌斗争的遗传免疫活化器。 GNTbm, a Taiwan-based biotech firm, has received U.S. FDA approval to begin Phase I clinical trials for its oral anti-cancer drug GNTbm-38, an epigenetic immunoactivator designed to boost the immune system’s fight against cancer. 该药物经过五年的开发,并以广泛的临床预科数据为后盾,针对多种癌症,从复发或易腐性边缘T细胞淋巴瘤开始。 The drug, developed over five years and backed by extensive preclinical data, targets multiple cancers, starting with relapsed or refractory peripheral T-cell lymphoma. 它可能有资格获得孤儿药物地位,并可与现有的免疫疗法相结合。 It may qualify for orphan drug status and could be combined with existing immunotherapies. 美国、中国和台湾计划进行多国试验, 在此之前该公司在癌症药物开普达(Kepida)上取得了成功。 Multinational trials are planned in the U.S., China, and Taiwan, following the company’s earlier success with the cancer drug Kepida.